Author Archives: Forest Ray PhD

Affiris Announces Phase 2 Study of Potential Parkinson’s Vaccine

Affiris is preparing for a Phase 2 clinical trial to test Affitope (PD01A), an experimental medicine that, if successful, could lead to a vaccine against  Parkinson’s disease. Affitope triggers the production of antibodies — molecules that recognize specific targets — against alpha-synuclein, a protein found in the…

Dosing Underway in Phase 1 Trial of AL101 for Potential Treatment of Parkinson’s, Other Disorders

Dosing has begun for healthy volunteers in a Phase 1 clinical trial of AL101, which has the potential to treat neurodegenerative disorders such as Parkinson’s, Alector recently announced. The randomized, placebo-controlled trial (NCT04111666) is testing the safety, tolerability, pharmacokinetics (how the compound moves throughout the body), and pharmacodynamics…

Ask an expert survey graphic

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums